 Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 | | 1997 | 2 | 2 | 4 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 4 | 6 | | 2000 | 1 | 0 | 1 | | 2002 | 2 | 3 | 5 | | 2003 | 4 | 3 | 7 | | 2004 | 1 | 2 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 7 | 5 | 12 | | 2007 | 1 | 4 | 5 | | 2008 | 11 | 1 | 12 | | 2009 | 5 | 3 | 8 | | 2010 | 5 | 6 | 11 | | 2011 | 3 | 5 | 8 | | 2012 | 7 | 2 | 9 | | 2013 | 9 | 5 | 14 | | 2014 | 11 | 4 | 15 | | 2015 | 13 | 10 | 23 | | 2016 | 11 | 9 | 20 | | 2017 | 16 | 9 | 25 | | 2018 | 15 | 17 | 32 | | 2019 | 24 | 14 | 38 | | 2020 | 23 | 25 | 48 | | 2021 | 25 | 27 | 52 | | 2022 | 6 | 27 | 33 | | 2023 | 3 | 29 | 32 | | 2024 | 12 | 17 | 29 | | 2025 | 19 | 13 | 32 | | 2026 | 11 | 1 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Hofmeister E, Major A. Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era. Curr Hematol Malig Rep. 2026 Aug 07; 21(1).
-
Jacobsen LM, Cuthbertson D, Felton J, Sherr JL, Simmons KM, Hosford J, Ismail HM, Greenbaum CJ, Wherrett DK, Pinckney A, Sanda S, DiMeglio LA, Higdon LE, Evans-Molina C. Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile. Diabetes Care. 2026 Aug 01; 49(8):1428-1433.
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
-
Fukuda R, Fujiwara Y, Maruyama T, Komohara Y. CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies. Front Immunol. 2026; 17:1852700.
-
O'Leary S, Fu AY, Rogers VA, Perdikis B, Farid M, Darko K, Srinivasan S, Barrie U, Khan HA, Sun MZ, Patel A. Optimal timing of PD-1 inhibitor immunotherapy administration to stereotactic radiosurgery in malignant gliomas: a propensity score-matched multi-institutional cohort study. J Neurosurg. 2026 Aug 01; 145(2):378-389.
-
Wong EYT, Damle SR, Shiu KK, Cohen SA, Lieu CH. Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520600.
-
Duffy JT, Martin-Regalado A, Haupt BE, Pogue JR, Thakur A, Cota MF, Zannikou M, Misener S, Krymskaya VP, McCortney K, Miska J, Horbinski C, Simberg D, Lesniak MS, James CD, Stupp R, Balyasnikova IV. Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors. Adv Sci (Weinh). 2026 Jun; 13(35):e22391.
-
DiLisio JE, Beard KS, Neef T, Miller SD, Wenzlau JM, Nakayama M, D'Antonio MA, Jamison BL, Nicholson KS, Baker RL, Brunetti TM, Gapin L, Haskins K. Antigen-specific immunotherapy with a CD4+ T cell neoepitope restrains CD8+ T cell differentiation in murine pancreatic islet grafts. Nat Commun. 2026 Mar 24; 17(1).
-
Shi Q, Gong N, Wang J, Palanki R, Zheng Q, Alameh MG, Dwivedi G, Davis B, Melamed J, Luo Z, Xu J, Figueroa-Espada CG, Xue L, Zeng Y, Han X, Kim D, Chen Q, Yamagata H, Geisler HC, El-Mayta R, Yoon IC, Weissman D, Mitchell MJ. Prodrug-tethered lipid nanoparticles for synergistic messenger RNA cancer immunotherapy. Nat Nanotechnol. 2026 Mar; 21(3):430-442.
-
Herb J, Bassett RL, Torres-Cabala CA, Prieto VG, Patel SP, Holder AM, Fisher SB, Lucci A, Wargo J, Amaria RN, Davies MA, Glitza Oliva IC, Tawbi HA, McQuade J, Ikeguchi AP, Wong MK, Diab AK, Gershenwald JE, Ross MI, Weiser R. Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection. Ann Surg Oncol. 2026 Jul; 33(7):6700-6708.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|